Hepatocyte Growth Factor Pipeline Review, H2 2019
Summary
Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF pipeline Target constitutes close to 13 molecules. The latest report Hepatocyte Growth Factor Pipeline Review, H2 2019, outlays comprehensive information on the Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF Hepatocyte growth factor HGF is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and nonepithelial organs including the heart and brain via antiapoptotic and antiinflammatory signals. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 1, 3 and 2 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders and Metabolic Disorders which include indications Amyotrophic Lateral Sclerosis, Colorectal Cancer, Critical Limb Ischemia, Gastric Cancer, Glioblastoma Multiforme GBM, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Acute Renal Failure ARF Acute Kidney Injury, Acute Spinal Cord Injury, Advanced Malignancy, Alzheimer's Disease, Arteriosclerosis, Breast Cancer, Cervical Cancer, Colon Cancer, Coronary Artery Disease CAD Ischemic Heart Disease, Diabetic Ischemic Foot Ulcers, Diabetic Neuropathic Pain, Gallbladder Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer Renal Cell Cancer, Leiomyosarcoma, Liver Cancer, Lymphedema, Lymphoma, Metastatic Cancer, Myocardial Infarction, Nasopharyngeal Cancer, Neuro Muscular Disorders, NonSmall Cell Lung Cancer, Parkinson's Disease, Peripheral Arterial Disease PAD/ Peripheral Vascular Disease PVD, PostOperative Pain, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar and Thromboangiitis obliterans Buerger disease.
Furthermore, this report also reviews key players involved in Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Scope
The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF
The report reviews Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF targeted therapeutics and enlists all their major and minor projects
The report assesses Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor Hepatopoietin A or Scatter Factor or HGF development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope